LncRNA SRA mediates cell migration, invasion, and progression of ovarian cancer via NOTCH signaling and epithelial-mesenchymal transition

Lee Kyung Kim, Sun Ae Park, Yoolhee Yang, Young Tae Kim, Tae Hwe Heo, Hee Jung Kim

Research output: Contribution to journalArticlepeer-review

7 Citations (Scopus)


Long non-coding RNA (lncRNA) is a newly identified regulator of tumor formation and tumor progression. The function and expression of lncRNAs remain to be fully elucidated, but recent studies have begun to address their importance in human health and disease. The lncRNA, SRA, known as steroid receptor activator, acts as an important modulator of gynecological cancer, and its expression may affect biological functions including proliferation, apoptosis, steroid formation, and muscle development. However, it is still not well known whether SRA is involved in the regulation of ovarian cancer. The present study investigated the molecular function and association between SRA expression and clinicopathological factors. In ovarian cancer cell lines, SRA knockdown and overexpression regulated cell migration, proliferation, and invasion. Both in vivo and in vitro experiments using knockdown and overexpression showed that SRA potently regulated epithelial-mesenchymal transition (EMT) and NOTCH pathway components. Further, clinical data confirmed that SRA was a significant predictor of overall survival (OS) and progression-free survival and patients with ovarian cancer exhibiting high expression of SRA exhibited higher recurrence rates than patients with low SRA expression. In conclusion, the present study indicates that SRA has clinical significance as its expression can predict the prognosis of ovarian cancer patients. High expression of the lncRNA SRA is strongly correlated with recurrence-free survival of ovarian cancer patients.

Original languageEnglish
Article numberBSR20210565
JournalBioscience Reports
Issue number9
Publication statusPublished - 2021 Sept

Bibliographical note

Funding Information:
The human epithelial ovarian cancer cell line SKOV3 was purchased from the Korean Cell Line Bank (KCLB, Seoul, South Korea) and the A2780 cell line was purchased from the European Collection of Authenticated Cell Cultures (Sigma–Aldrich, ECACC, St. Louis, MO, U.S.A.). Ovarian cancer cell lines OVCA429, OVCA433, HOSE, and TOV112D were provided by the Korean Gynecological Cancer Bank through the Biomedical Technology Development Program of the Ministry of Science, Information and Communication Technology and Future Planning (MSIP), Korea. OVCAR3, SKOV3, and A2780 cells were cultured in RPMI-1640 medium (Gibco, Gaithersburg, MD, U.S.A.). OVCA429, OVCA433, and TOV112D cells were cultured in Dulbecco’s modified Eagle’s medium. The HOSE cell line was cultured in ovarian epithelial cell medium (ScienCell, OEpiCM, Carlsbad, CA, U.S.A.). All culture media were supplemented with 10% (vol/vol) fetal bovine serum, 1% antibiotic–antimycotic and 1% penicillin/streptomycin. Cells were cultured in an environment maintained at 37◦C in a humid atmosphere of 5% CO2 and 95% air. The culture medium was changed with fresh medium every 2–3 days and the cells were used at passages between 5 and 10.

Funding Information:
This work was supported by the Korea Health Technology R&D Project through the Korea Health Industry Development Institute, funded by the Ministry of Health and Welfare, Republic of Korea [grant number HI17C0321]; and the Basic Science Research Program through the National Research Foundation of Korea (NRF), funded by the Ministry of Education, Science and Technology [grant numbers NRF-2018R1D1A1B07049780, 2018R1A6A1A03025108, 2018R1D1A1B07049578, 2021R1A2C2009782].

Publisher Copyright:
© 2021 The Author(s).

All Science Journal Classification (ASJC) codes

  • Biophysics
  • Biochemistry
  • Molecular Biology
  • Cell Biology


Dive into the research topics of 'LncRNA SRA mediates cell migration, invasion, and progression of ovarian cancer via NOTCH signaling and epithelial-mesenchymal transition'. Together they form a unique fingerprint.

Cite this